Literature DB >> 12529932

VPAC receptors for VIP and PACAP.

M Laburthe1, A Couvineau, J C Marie.   

Abstract

VIP and PACAP are two prominent neuropeptides that share two common G protein-coupled receptors, VPAC1 and VPAC2, while PACAP has an additional specific receptor, PAC1. This article reviews the present knowledge regarding various aspects of VPAC receptors including: 1) receptor specificity toward natural VIP-related peptides and pharmacology of synthetic agonists or antagonists; 2) genomic organization and chromosomal localization; 3) signaling and established or putative interactions with G proteins or accessory proteins such as RAMPs or PDZ-containing proteins; 4) molecular basis of ligand-receptor interaction as determined by site-directed mutagenesis, construction of receptor chimeras, and structural modeling; 5) constitutively active receptor mutants; 6) short-term (desensitization, internalization, phosphorylation) and long-term (transcription) regulations and transgenic models; 7) receptor polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12529932

Source DB:  PubMed          Journal:  Recept Channels        ISSN: 1060-6823


  52 in total

Review 1.  Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.

Authors:  Kuntal Pal; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

Review 2.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Direct interactions between calcitonin-like receptor (CLR) and CGRP-receptor component protein (RCP) regulate CGRP receptor signaling.

Authors:  Sophie C Egea; Ian M Dickerson
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

4.  Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17 cells.

Authors:  Wanhong Ding; Michela Manni; Lori L Stohl; Xi K Zhou; John A Wagner; Richard D Granstein
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

5.  Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand.

Authors:  Christy Rani R Grace; Marilyn H Perrin; Jozsef Gulyas; Michael R Digruccio; Jeffrey P Cantle; Jean E Rivier; Wylie W Vale; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-12       Impact factor: 11.205

6.  Microarray analyses of pituitary adenylate cyclase activating polypeptide (PACAP)-regulated gene targets in sympathetic neurons.

Authors:  Karen M Braas; Kristin C Schutz; Jeffrey P Bond; Margaret A Vizzard; Beatrice M Girard; Victor May
Journal:  Peptides       Date:  2007-04-19       Impact factor: 3.750

Review 7.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

8.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS.

Authors:  Chaohong Sun; Danying Song; Rachel A Davis-Taber; Leo W Barrett; Victoria E Scott; Paul L Richardson; Ana Pereda-Lopez; Marie E Uchic; Larry R Solomon; Marc R Lake; Karl A Walter; Philip J Hajduk; Edward T Olejniczak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

9.  The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.

Authors:  Chaneun Nam; Adam J Case; Bruce S Hostager; M Sue O'Dorisio
Journal:  J Mol Neurosci       Date:  2008-07-29       Impact factor: 3.444

10.  VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome.

Authors:  Shoko Nakayama; Taiji Yokote; Kichinosuke Kobayashi; Yuji Hirata; Tetsuya Hiraiwa; Izumi Komoto; Kazuho Miyakoshi; Yoshiko Yamakawa; Takayuki Takubo; Motomu Tsuji; Masayuki Imamura; Toshiaki Hanafusa
Journal:  Endocrine       Date:  2009-01-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.